Home/Filings/4/0000950170-25-054712
4//SEC Filing

McIntyre David 4

Accession 0000950170-25-054712

CIK 0001750149other

Filed

Apr 15, 8:00 PM ET

Accepted

Apr 16, 4:06 PM ET

Size

5.3 KB

Accession

0000950170-25-054712

Insider Transaction Report

Form 4
Period: 2025-04-14
McIntyre David
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-04-14+1,775,5391,775,539 total
    Exercise: $2.00Exp: 2035-04-14Common Stock (1,775,539 underlying)
Footnotes (1)
  • [F1]25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.

Documents

1 file

Issuer

Inhibikase Therapeutics, Inc.

CIK 0001750149

Entity typeother

Related Parties

1
  • filerCIK 0001404254

Filing Metadata

Form type
4
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 4:06 PM ET
Size
5.3 KB